NRX Pharmaceuticals (NRXP) Return on Sales (2025 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly Return on Sales of 0.05% for Q1 2026, up 9.33% quarter-over-quarter from 0.05% in Q4 2025.

NRX Pharmaceuticals (NRXP) Return on Sales (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Return on Sales for 2 consecutive years, with 0.05% the latest figure, recorded in Q1 2026.

In Q1 2026, Return on Sales changed N/A year-over-year to 0.05%; the TTM figure through Mar 2026 stood at 0.08% (changed N/A YoY), while the FY2025 annual figure was 0.56%, changed N/A from the prior year.
Return on Sales improved to 0.05% in Q1 2026 per NRXP's latest filing, from 0.05% in the prior quarter.
Across five years, Return on Sales topped out at 0.05% in Q1 2026 and bottomed at 0.21% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	NRX Pharmaceuticals	132.53 Mn	105.83 Mn	426,000.00	-0.06%

Download Data